Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05427162 · ClinicalTrials.gov registry record · Phase 1
A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist
A Phase 1 study, sponsored by Actelion.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT05427162 is a Phase 1 study that has completed, run by Actelion. The registered enrollment target is 88 participants.
The verdict
NCT05427162, a Phase 1 study, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
The purpose of the study is to assess safety and tolerability of prostacyclin receptor agonist formulation in treatment period 1 and with different formulation of prostacyclin receptor agonist in treatment period 2.
Interventions
- DRUG Prostacyclin Receptor Agonist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2022-06-21 |
| Est. Completion | 2023-12-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05427162
The ClinicalTrials.gov registry entry for NCT05427162 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Prostacyclin Receptor Agonist is the first listed.
NCT05427162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05427162 about?
NCT05427162 is a clinical study titled "A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist". The purpose of the study is to assess safety and tolerability of prostacyclin receptor agonist formulation in treatment period 1 and with different formulation of prostacyclin receptor agonist in treatment period 2.
What is the current status of trial NCT05427162?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2022-06-21. Estimated completion is 2023-12-05.
What interventions are being tested in trial NCT05427162?
The interventions under investigation include: Prostacyclin Receptor Agonist (DRUG).
Who is sponsoring clinical trial NCT05427162?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.